Clinical Edge Journal Scan

Identifying potential risks factors for PsA


 

Key clinical point: A previous diagnosis of gout, uveitis, metabolic and lifestyle factors like obesity, alcohol consumption, and infections like pharyngitis and skin infections were potential risk factors for psoriatic arthritis (PsA), whereas statin use showed a negative association with PsA.

Major finding: A previous diagnosis of gout (odds ratio [OR], 2.19), uveitis (OR, 3.79), alcohol use (OR, 1.67), obesity (OR, 1.64), pharyngitis (OR, 1.23), and skin infection (OR, 1.37; all P < .001) were significant risk factors for PsA. The use of statin was negatively associated with PsA (OR, 0.53; P < .001).

Study details: This was a set of 4 separate case-control studies conducted in parallel and included cases of incident PsA (n=7,594), psoriasis (n=111,375), rheumatoid arthritis (RA; n=28,341), and ankylosing spondylitis (AS; n=3,253) matched to control participants (PsA, n=75,930; psoriasis, n=1113,345; RA, n=283,226; and AS, n=32,530).

Disclosures: This work was supported by grants from the National Institute of Health and internal grants from the University of Pennsylvania. Dr. Gelfand, Dr. Love, and Dr. Ogdie declared receiving research grants, honoraria, and reimbursement from and/or serving as a consultant for various sources.

Source: Meer E et al. J Rheumatol. 2021 Aug 1. doi: 10.3899/jrheum.210006 .

Recommended Reading

Psoriatic arthritis health care costs continue to rise over time
Psoriatic Arthritis ICYMI
Bimekizumab approved in Europe for psoriasis treatment
Psoriatic Arthritis ICYMI
PsA: Guselkumab demonstrates clinically meaningful and sustained improvement in fatigue
Psoriatic Arthritis ICYMI
Burden of psoriasis is mild in early PsA but impacts HRQoL
Psoriatic Arthritis ICYMI
Treating skin with biologics may reduce risk of developing PsA in patients with psoriasis
Psoriatic Arthritis ICYMI
JAK inhibitors safe and effective over placebo for PsA
Psoriatic Arthritis ICYMI
Secukinumab provides low radiographic progression over 2 years in patients with PsA
Psoriatic Arthritis ICYMI
Secukinumab effective for PsA, with high patient satisfaction in the real world
Psoriatic Arthritis ICYMI
Oligoarticular PsA similar to polyarticular PsA with few exceptions
Psoriatic Arthritis ICYMI
No clinically relevant increase in mortality in patients with PsA
Psoriatic Arthritis ICYMI